We offer a variety of modified rNTPs suitable for in vitro transcription. This includes the Pseudo-UTP and 5-Methyl-CTP used to reduce cellular response against mRNA. It is now well established that a full substitution with these two modified rNTP reduces the innate immune response of cells. Such modRNA, as called by Pr Chien’s team in their article Nat. Biotechnol. in 2013 (10.1038/nbt.2682), can be used as treatment in vivo with no more need for HPLC purification. They showed that intramyocardial injection of VEGF-A coding modRNA after myocardial infarction (MI) induces vascular regenration (see picture below).

Extract from Zangi et al 2013 Nat Biotechnol. illustrating the use of modRNA as treatment of myocardial infarction (MI)